Loading clinical trials...
Loading clinical trials...
A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part I
Conditions
Interventions
PDC-1421 Capsule
Locations
1
United States
UCSF Medical Center
San Francisco, California, United States
Start Date
December 1, 2019
Primary Completion Date
July 15, 2020
Completion Date
July 15, 2020
Last Updated
December 1, 2021
Lead Sponsor
BioLite, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions